Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Scientists at Columbia University, Ludwig Institute Clinical Trial Center detail research in cancer vaccines
February 27th, 2007
Researchers detail in "Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen," new data in cancer vaccines. According to recent research from the United States, "Identification of immunodominant CD8(+) T cell responses to frequently expressed tumor antigens across MHC class I polymorphism is essential for the implementation of cancer immunotherapy. However, the key factors that determine immunodominance are not fully understood." "Because of its frequent expression in tumors and its spontaneous immunogenicity, NY-ESO-1 is a prime target of cancer vaccines and an ideal model antigen for elucidating...
Source: Cancer Weekly (2007-02-27)
|
